Northern Ireland Children with Duchenne Muscular Dystrophy Gain Access to Givinostat Through Early Access Programme
Key Insights
Approximately 16 boys with Duchenne Muscular Dystrophy (search) in Northern Ireland will gain access to givinostat through the Belfast Health Trust (search)'s Early Access Programme, bringing the region in line with the rest of the UK.
Patients must meet specific criteria including being over six years of age and mobile, with treatment potentially starting by mid-October for eligible children.
The anti-inflammatory drug givinostat has been approved by UK medicines regulators and could potentially extend mobility for children with this severe inherited muscular dystrophy (search) that typically confines patients to wheelchairs.
Approximately 16 boys with Duchenne Muscular Dystrophy (search) (DMD (search)) in Northern Ireland will gain access to the anti-inflammatory drug givinostat through the health service, following a decision by the Belfast Health Trust (search) to participate in the Early Access Programme. The move brings Northern Ireland in line with the rest of the UK for access to this treatment for one of the most severe forms of inherited muscular dystrophy (search).
Treatment Access and Eligibility
The drug will be available to patients who meet specific criteria, including being more than six years of age and mobile. Eligible children could begin treatment by mid-October, with some families already receiving letters from the Belfast Trust (search) outlining the potential treatment changes. The Belfast Trust has committed to making the process as "smooth as possible" for families.
Givinostat has been approved for use in the UK by the medicines regulator and is available through the NHS for people who meet strict criteria under the Early Access Programme, which requires individual trusts to apply for participation.
Patient Impact and Family Response
The announcement has brought significant relief to affected families. Alfie Pentony, a 13-year-old from Newry and keen Newcastle United supporter, described the news as "absolutely brilliant" for himself and other boys with the condition. "I was so happy, I was nearly crying," Alfie said, expressing hope that the drug would enable him to play football "even longer."
His father, Jamie Pentony, characterized the development as "massive news" and "immense" for both Alfie and the broader DMD (search) community. He described the previous lack of access as deeply frustrating, stating: "There was a weight on our shoulders, it felt like every day we weren't getting access to the drug was the day we were letting Alfie down. But today is a day to celebrate, today is a day to be happy."
Disease Background and Treatment Potential
DMD (search) is one of the most common and severe forms of muscular dystrophy (search), predominantly affecting boys in early childhood. The condition is caused by alterations in a protein called dystrophin (search), which leads to muscle fiber breakdown. These fibers are subsequently replaced by fibrous or fatty tissues, causing progressive muscle weakness that often leads to patients becoming immobile and confined to wheelchairs.
The condition affects approximately 2,500 people in the UK at any given time, with many patients typically living only into their 20s or 30s. For patients like Alfie, givinostat could potentially provide additional years of mobility, representing a significant therapeutic advance in managing this devastating inherited genetic condition that gradually causes muscles to weaken and leads to increasing disability.